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Introduction
Cardiac and renal functioning are highly
related as each system is interdependent
on the other, and subsequently,
dysfunction of one system can potentiate
the development of dysfunction of the
other, a conditioned referred to as
Cardiorenal Syndrome, or CRS. (Scully &
Goldsmith, 2013). In CRS, heart failure and
renal failure exist together. Heart failure is
the result of decreased heart efficiency and
results in hemodynamic and
neurohormonal changes (Nicholson, 2014).
A decrease in cardiac function and cause
dysfunction of other body systems,
including the renal system, and at the same
time, impaired renal functioning can result
in increased fluid retention and increased
systemic vascular resistance and can prove
to be detrimental to cardiac function.
According to Giam, et al., (2015), the
prevalence of heart failure is expected to
rise nearly 46% from 2012 to 2030
secondary to the increase in obesity and
associated comorbid conditions. With the
prevalence of heart failure expected to rise
drastically, renal dysfunction associated
with heart failure is expected to rise as
well, with heart failure being responsible
for nearly 44% of deaths in patients with
end-stage renal disease (Giam, et al.,
2015). Cardiorenal syndrome can be
divided in to five separate sub-classes.
A significant portion of the
interdependence of cardiac and renal
functioning is related to neurohormonal
mechanisms, most notably the renin
angiotensin aldosterone system, or RAAS.
For this reason, angiotensin converting
enzyme and inhibitors (ACE-I) have become
a main stay for the treatment of heart
failure, however, ACE-I’s can potentially
have detrimental renal effects (Valika &
Gheorghiade, 2012). This can make the
management of CRS difficult for
practitioners and special considerations
must be made. Cardiorenal Syndrome can
present a complex challenge for
practitioners and with new evidence-based
research being released, there exists the
possibility for growth and understanding.

Signs and Symptoms Nursing Implications
The signs and symptoms associated
with CRS are similar to those
experienced in heart failure. The signs
and symptoms are the result of cardiac
and renal dysfunction compounded
together. The New York Heart
Association classification scale can be
used to describe symptoms.
Class I heart failure is associated with
no limitations to ordinary activity and
can progress to class IV, in which
symptoms are present even at rest and
activity only exacerbates discomfort.
Other signs and symptoms include:
Ø Orthopnea
Ø Paroxysmal Nocturnal Dyspnea (PND)
Ø Reduced Activity Tolerance
Ø Chest pain
Ø Edema
Ø 2 to 3 kilogram weight gain per week
Ø Pulmonary edema and crackles
Ø Arrhythmias
Patients should be educated on warning
signs of complications and what should
be done when acute issues and
complications arise. Quick intervention
can reduce the likelihood of
exacerbations

Classification

Underlying Pathophysiology

Significance

Cardiorenal Syndrome is a complex
Nearly five million people in the United
condition. Normal compensatory
The common pathological mechanism of CRS is the chronic activation of the RAAS
States are diagnosed with heart failure,
mechanisms used to maintain
and another half a million each year.
resulting in oxidative stress leading to impaired cardiac and renal functioning. When
There is a significant economic burden as cardiac output is decreased, hypoperfusion of the kidneys and a decrease in glomerular homeostasis actually become deleterious
for both cardiac and renal functioning.
filtration rate (GFR) can result. This decrease in perfusion results in the stimulation of
well, with nearly $39 billion associated
The significance of the pathophysiology
costs in 2010 (Coons, McGraw, & Murali, the RAA system, a normal mechanism of compensation. Activation of the RAA system
lies in the management of CRS.
results in several changes. First, conversion of angiotensin to angiotensin II results in
2011). Lifestyle modifications should
Ø Treatment of CRS involves choices
include the elimination of behaviors that vasoconstriction, in turn, increased systemic vascular resistance and blood pressure.
that are contradictory
Second, Aldosterone is stimulated to be released from the adrenal cortex. Aldosterone
can further decrease cardiac function.
results in the retention of fluid and sodium from the kidneys. The net effects of the RAA Ø Cornerstone of management is ACE-I,
Modifiable lifestyle factors include:
but use can worsen renal functioning
Ø Smoking
system is increased blood volume and systemic vascular resistance to increase renal
as indicated by elevated serum
perfusion. A negative feedback system then inhibits the RAA system once homeostasis is
Ø Diet
creatinine and BUN levels (House, et
Ø Exercise
returned (Klabunde, n.d.).
al., 2010).
Ø Alcohol use
Ø Diuretics are used to reduce preload,
Education is essential to reduce the risks
have been shown to be beneficial in
associated with medications used in CRS
heart failure
management, especially hypotension.
Ø Similar to ACE-I, diuretics can have
Patients should be educated to:
negative renal effects and further
Ø Eliminate the use of NSAID’s which
complicate CRS.
can decrease renal function and
should be taught to
Ø limit salt substitutes (often low
sodium diets are implemented), as
the replacements can be high it
potassium (O’Donovan, 2014).
Ø Serum potassium and creatinine
levels should be monitored by
practitioners for the assessment of
renal function. At the initiation of an
ACE-I, renal function should be
monitored, and as dosing is adjusted
according to O’Donovan (2014).

Conclusion
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Description
Figure 1. Cardiorenal Syndrome (House, et al., 2010).

Class I

acute cardiac injury results in renal
injury

Class II

heart failure leading to chronic renal
failure

Class III

acute kidney injury resulting in cardiac
injury

Class IV

chronic renal failure leading to heart
failure

Class V

cardiac and renal dysfunction
secondary to a systemic disease
Table 1. Classifications of CRS (House, et al., 2010).

In Cardiorenal syndrome however, a normal compensatory mechanism becomes
chronically activated, resulting in deleterious effects that can potentiate the failure of
both cardiac and renal functioning. Chronic activation of the RAA system can result in
hypertrophy, inflammation, apoptosis, and oxidative stress. Angiotensin II appears to be
a significant contributor in CRS. A chronic elevation of angiotensin II has been shown to
induce apoptosis in renal and cardiac cells as well as activation of NADPH oxidase.
NADPH leads to increased reactive oxygen species (ROS) which in turn reduces the
availability of nitric oxide (vasodilating effects in normal circumstances) and increased
vasoconstriction. The increased levels of ROS also stimulate the production of proinflammatory mediators. The best understood mediators are interleukin-6 and
transforming growth factor-beta, which contribute to fibrosis in both the heart and
kidneys. Fibrotic tissue results in a change of structure, producing a change of function.
Angiotensin II is also responsible for the stimulation and release of aldosterone, which
when chronically activated, can cause increased collagen formation and further
increasing fibrosis (Giam, et al., 2016). According to Koniari, et al. (2010), the cytokines
produced also have a negative inotropic effect, which causes a further reduction in
cardiac output and renal perfusion. When combined together, all components lead to
decreased functioning of cardiac and renal systems. Other deleterious effects of chronic
activation of RAA system includes an increased preload and afterload, which can
complicate heart failure further.

Figure 2. RAA System (Klabunde, 2014).

